TEVA PHARMACEUTICAL INDUSTRIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.81 USD | +4.23% |
|
+7.39% | +32.28% |
ETFs positioned on Teva Pharmaceutical Industries Limited
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.38% | 13 M€ | -.--% | ||
| 0.27% | 18 M€ | +3.79% | - | |
| 0.06% | 10 M€ | -3.35% | - | |
| 0.04% | 7 M€ | +1.95% | - | |
| 0.04% | 284 M€ | -.--% | ||
| 0.02% | 786 M€ | -.--% | ||
| 0.02% | 23 M€ | -.--% | - | |
| 0.02% | 1,166 M€ | +0.26% | - | |
| 0.02% | 607 M€ | +0.05% | - | |
| 0.02% | 206 M€ | -.--% | ||
| 0.02% | 273 M€ | +15.83% | ||
| 0.00% | 237 M€ | +2.89% | - |
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
13.81
USD
Average target price
15.74
USD
Spread / Average Target
+13.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.28% | 15.64B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- TEVA Stock
- Funds and ETFs Teva Pharmaceutical Industries Limited
